Predictors of outcome in children with Langerhans cell histiocytosis
- 14 March 2005
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 45 (1) , 37-42
- https://doi.org/10.1002/pbc.20364
Abstract
Background Our goal was to examine the clinical course of patients with Langerhans cell histiocytosis (LCH), with a special emphasis on bone disease and to attempt to identify and examine the factors that may predict reactivation and overall prognosis. Procedure We conducted a retrospective chart review of 132 consecutive pediatric patients treated at Children's Hospital Los Angeles for LCH from 1984 to 2001. Results The risk for reactivation after initial management is significantly higher for patients with multiple bone and those with multiple organ involvement as compared with patients who had a single bone lesion (hazard ratios are 7.1 and 11.6). Patients younger than 1 year in the multiple organ group have an increased risk of death at 2 years when compared with the older patients in that group (hazard ration = 6.2, P = 0.022). Endocrine abnormalities were seen in 20% and 7.5% of patients with or without skull lesions respectively. Conclusions Patients with LCH involving only the bones have a significantly better outcome than those with other organ involvement. Patients with multiple organ involvement who are less than 1 year of age are at high risk of death and should be approached more aggressively upfront. Pediatr Blood Cancer 2005; 45:37–42.Keywords
This publication has 23 references indexed in Scilit:
- Endocrine involvement in pediatric-onset langerhans' cell histiocytosis: a population-based studyThe Journal of Pediatrics, 2004
- Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study GroupBone Marrow Transplantation, 2003
- Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimenBone Marrow Transplantation, 2003
- 2-Chlorodeoxyadenosine Therapy for Disseminated Langerhans Cell HistiocytosisMayo Clinic Proceedings, 2003
- Response to initial treatment of multisystem langerhans cell histiocytosis: An important prognostic indicatorMedical and Pediatric Oncology, 2002
- Treatment of Multisystem Langerhans Cell Histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 StudiesKlinische Padiatrie, 2000
- PERMANENT DISABILITIES IN CHILDHOOD SURVIVORS OF LANGERHANS CELL HISTIOCYTOSISPediatric Hematology and Oncology, 2000
- Langerhans cell histiocytosisThe Journal of Pediatrics, 1995
- Langerhans Cell HistiocytosisNew England Journal of Medicine, 1987
- Allogeneic Bone Marrow Transplantation in a Patient with Chemotherapy-Resistant Progressive Histiocytosis XNew England Journal of Medicine, 1987